Expert opinion on drug delivery最新文献_第3页

Polyphosphoester cubosomes: introducing a novel drug delivery system.

Expert opinion on drug delivery Pub Date : 2025-03-25 DOI: 10.1080/17425247.2025.2484309

Frederik R Wurm

引用次数: 0

The blood-brain barrier as a treatment target for neurodegenerative disorders.

Expert opinion on drug delivery Pub Date : 2025-03-21 DOI: 10.1080/17425247.2025.2480654

Ruslan Rust, Abhay P Sagare, Mingzi Zhang, Berislav V Zlokovic, Kassandra Kisler

{"title":"The blood-brain barrier as a treatment target for neurodegenerative disorders.","authors":"Ruslan Rust, Abhay P Sagare, Mingzi Zhang, Berislav V Zlokovic, Kassandra Kisler","doi":"10.1080/17425247.2025.2480654","DOIUrl":"10.1080/17425247.2025.2480654","url":null,"abstract":"Introduction: The blood-brain barrier (BBB) is a vascular endothelial membrane which restricts entry of toxins, cells, and microorganisms into the brain. At the same time, the BBB supplies the brain with nutrients, key substrates for DNA and RNA synthesis, and regulatory molecules, and removes metabolic waste products from brain to blood. BBB breakdown and/or dysfunction have been shown in neurogenerative disorders including Alzheimer's disease (AD). Current data suggests that these BBB changes may initiate and/or contribute to neuronal, synaptic, and cognitive dysfunction, and possibly other aspects of neurodegenerative processes.Areas covered: We first briefly review recent studies uncovering molecular composition of brain microvasculature and examine the BBB as a possible therapeutic target in neurodegenerative disorders with a focus on AD. Current strategies aimed at protecting and/or restoring altered BBB functions are considered. The relevance of BBB-directed approaches to improve neuronal and synaptic function, and to slow progression of neurodegenerative processes are also discussed. Lastly, we review recent advancements in drug delivery across the BBB.Expert opinion: BBB breakdown and/or dysfunction can significantly affect neuronal and synaptic function and neurodegenerative processes. More attention should focus on therapeutics to preserve or restore BBB functions when considering treatments of neurodegenerative diseases and AD.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1-20"},"PeriodicalIF":0.0,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143652810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A look to the future: cyclodextrins and cyclodextrin-based drug delivery to the retina.

Expert opinion on drug delivery Pub Date : 2025-03-20 DOI: 10.1080/17425247.2025.2482049

Phatsawee Jansook, Hákon H Sigurdsson, Thorsteinn Loftsson

{"title":"A look to the future: cyclodextrins and cyclodextrin-based drug delivery to the retina.","authors":"Phatsawee Jansook, Hákon H Sigurdsson, Thorsteinn Loftsson","doi":"10.1080/17425247.2025.2482049","DOIUrl":"10.1080/17425247.2025.2482049","url":null,"abstract":"Introduction: Retinal diseases are a leading cause of vision loss, affecting millions of people worldwide. Current treatment options are based on invasive methods such as intravitreal injections. Therefore, there is a need for alternative therapeutic strategies that are both effective and more patient-friendly.Areas covered: Topical drug delivery has gained attention as a preferred noninvasive approach, although it is hindered by several ocular barriers. Cyclodextrin (CD)-based nanoparticles have emerged as a promising strategy to overcome these limitations by enhancing drug permeability in the posterior segment of the eye. This review discusses the potential of CDs as enabling pharmaceutical excipients, their role in improving ocular drug bioavailability, and provides examples of CD-based eye drop formulations currently under development or undergoing clinical trials. Also, the role of CDs as active pharmaceutical agents in ophthalmology is discussed.Expert opinion: CD-based nanoparticle eye drops present a promising solution and have shown clinical success. CDs are approved pharmaceutical excipients for eye drop formulations and can act as active pharmaceutical ingredients for the treatment of inherent retinal diseases. Future innovations in hybrid CD-based delivery systems and integration of novel therapeutic compounds could provide more efficient and targeted treatment options for retinal diseases.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1-18"},"PeriodicalIF":0.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143660062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An overview of oral bioavailability enhancement through self-emulsifying drug delivery systems.

Expert opinion on drug delivery Pub Date : 2025-03-19 DOI: 10.1080/17425247.2025.2479759

Flavia Laffleur, Gioconda Millotti, Jennifer Lagast

{"title":"An overview of oral bioavailability enhancement through self-emulsifying drug delivery systems.","authors":"Flavia Laffleur, Gioconda Millotti, Jennifer Lagast","doi":"10.1080/17425247.2025.2479759","DOIUrl":"10.1080/17425247.2025.2479759","url":null,"abstract":"Introduction: The pharmaceutical technologists face a lot of challenges and limitations when designing novel drug delivery systems such as low oral bioavailability of many drugs, primarily due to poor solubility, slow dissolution rates, limited permeability through gastrointestinal mucosa, and rapid degradation within the body.Areas covered: The biopharmaceutical classification (BCS) classification represents a map in drug delivery research. Numerous active ingredients are characterized by low bioavailability due to poor water solubility, especially active ingredients of BCS class II and IV. Self-emulsifying drug delivery systems (SEDDS) could act as game changer in order to overcome the challenges and limitations of poor bioavailability. In this review, timelines representing the launch of self-emulsifying drug delivery systems, their introduction to the pharmaceutical platform and their benefits will be discussed in detail.Expert opinion: The development of multifunctional systems capable of combining controlled release, targeted delivery, and diagnostic capabilities is a promising avenue. As the technology matures, self-microemulsifying drug delivery systems and self-nanoemulsifying drug delivery systems are likely to become a standard approach for delivering BCS class II and IV drugs, transforming the pharmaceutical landscape.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1-13"},"PeriodicalIF":0.0,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143618088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular insights into the antineoplastic potential of apigenin and its derivatives: paving the way for nanotherapeutic innovations.

Expert opinion on drug delivery Pub Date : 2025-03-17 DOI: 10.1080/17425247.2025.2477664

Debasmita Dutta, Ashique Al Hoque, Brahamacharry Paul, Shahnaz Begum, Uday Aditya Sarkar, Biswajit Mukherjee

{"title":"Molecular insights into the antineoplastic potential of apigenin and its derivatives: paving the way for nanotherapeutic innovations.","authors":"Debasmita Dutta, Ashique Al Hoque, Brahamacharry Paul, Shahnaz Begum, Uday Aditya Sarkar, Biswajit Mukherjee","doi":"10.1080/17425247.2025.2477664","DOIUrl":"10.1080/17425247.2025.2477664","url":null,"abstract":"Introduction: Apigenin, a widely distributed bioactive flavonoid, has recently gained excellent attention among researchers as an effective anticancer drug that can alternate cancer-signaling pathways, induce programmed cell death, and reduce tumor growth in various cancer types. Despite its impressive anti-neoplastic activity, high hydrophobicity, and nonspecific biodistribution make apigenin difficult for pharmaceutical applications.Areas covered: We highlighted the therapeutic potential of apigenin and its derivatives in different cancer types, along with their mechanism of action. Nanoengineered drug delivery systems have remarkable applications in minimizing drug degradation and enhancing the therapeutic efficacy of drugs with sustained release, prolonged blood retention time, and reduced off-target toxicities. This review has evaluated and explored the molecular interactions of this novel flavonoid in various cancer signaling pathways to selectively inhibit neoplastic development in multiple cancer types. To ensure the complete coverage of the explored research area, Google Scholar, PubMed, and Web of Science were used to find not only the most relevant but also connected and similar articles.Expert opinion: A comprehensive overview of apigenin nanotherapy in cancer treatment can establish a platform to overcome its difficulties for pharmaceutical applications and efficient clinical translation from bench to bedside.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1-20"},"PeriodicalIF":0.0,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143598579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Performance characterization of spring-actuated prefilled pen devices for lebrikizumab and dupilumab.

Expert opinion on drug delivery Pub Date : 2025-03-13 DOI: 10.1080/17425247.2025.2477656

Rozhin Derakhshandeh, Javad Eshraghi, Milad Tavakolian, Kevin H Duffy, Jean-Christophe Veilleux, Galen H Shi, Pavlos P Vlachos

{"title":"Performance characterization of spring-actuated prefilled pen devices for lebrikizumab and dupilumab.","authors":"Rozhin Derakhshandeh, Javad Eshraghi, Milad Tavakolian, Kevin H Duffy, Jean-Christophe Veilleux, Galen H Shi, Pavlos P Vlachos","doi":"10.1080/17425247.2025.2477656","DOIUrl":"10.1080/17425247.2025.2477656","url":null,"abstract":"Background: Design parameters of prefilled pens, known as autoinjectors within the medical device community, can affect pen's functioning and user experience. This study compares the performance of two 2 mL prefilled pen devices: lebrikizumab (125 mg/mL) and dupilumab (150 mg/mL).Research design and methods: We recorded force and acoustic signals during administration from the prefilled pen devices and performed high-speed video recording during needle insertion and drug delivery. Measurements were reported in these categories: (i) The kinematics of needle movement during insertion captured by two cameras (ii) Injection flow rate and duration, and the time between acoustic 1st (activation) click and 2nd click sounds (iii) Post-2nd click injection duration, and (iv) delivered dose volume. We investigated the impact of temperature on device performance by experimenting at room temperature (~25℃) and cool condition (~5℃).Results: The lebrikizumab device demonstrated faster injection and more reliable end-of-dose indication, while the dupilumab device showed less lateral needle movement in air during insertion. The device activation forces are provided.Conclusion: Our investigation uncovered performance distinctions between lebrikizumab and dupilumab prefilled pens, which could potentially translate into patient experience, and varying levels of risk associated with intramuscular injection for the adult population and premature device removal.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1-10"},"PeriodicalIF":0.0,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143574867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current insights into drug-coated balloons for peripheral arterial disease.

Expert opinion on drug delivery Pub Date : 2025-03-12 DOI: 10.1080/17425247.2025.2476043

Antonio Micari, Antonino Micari, Vittorio Virga, Francesco Costa, Gianluca Di Bella, Giuseppe Roscitano, Antonio Versace, Giuseppe Vadalà, Giampiero Vizzari

{"title":"Current insights into drug-coated balloons for peripheral arterial disease.","authors":"Antonio Micari, Antonino Micari, Vittorio Virga, Francesco Costa, Gianluca Di Bella, Giuseppe Roscitano, Antonio Versace, Giuseppe Vadalà, Giampiero Vizzari","doi":"10.1080/17425247.2025.2476043","DOIUrl":"10.1080/17425247.2025.2476043","url":null,"abstract":"Introduction: Peripheral artery disease (PAD) is a manifestation of systemic atherosclerosis. It is often associated with coronary and/or cerebral vascular involvement, leading to a higher risk of cardiovascular and cerebrovascular events, among which myocardial infarction, stroke, and death. Cardiovascular prevention has proven effective in reducing the progression of the disease and early diagnosis leads to more rapid initiation of medical therapy. However, revascularization of the diseased segment represents the only solution in the manifest and symptomatic forms of the disease.Areas covered: Surgical treatment has historically represented the first treatment of PAD, which consists in the creation of bypasses excluding the obstructed segment. Nowadays, endovascular treatment represents in many cases the first line of intervention. Drug-coated balloons are a cornerstone solution for the treatment of peripheral lesions and are supported by multiple trials demonstrating their efficacy and safety.Expert opinion: New devices, such as sirolimus-eluting balloons, and also new eluting technologies will further improve the efficacy and the results of peripheral angioplasty. In the next years, we will experience the routinary use of new techniques currently under study. In this review, we will discuss the role of drug-coated balloons in the treatment of PAD.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1-9"},"PeriodicalIF":0.0,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143574861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent advances in the use of liquid crystalline nanoparticles for non-small cell lung cancer treatment. 利用液晶纳米粒子治疗非小细胞肺癌的最新进展。

Expert opinion on drug delivery Pub Date : 2025-03-07 DOI: 10.1080/17425247.2025.2474693

Thiagarajan Madheswaran, Dinesh Kumar Chellappan, Fiona Sze Nee Lye, Kamal Dua

{"title":"Recent advances in the use of liquid crystalline nanoparticles for non-small cell lung cancer treatment.","authors":"Thiagarajan Madheswaran, Dinesh Kumar Chellappan, Fiona Sze Nee Lye, Kamal Dua","doi":"10.1080/17425247.2025.2474693","DOIUrl":"10.1080/17425247.2025.2474693","url":null,"abstract":"Introduction: Non-small cell lung cancer (NSCLC) continues to pose a considerable health challenge with few therapeutic alternatives. Liquid crystalline nanoparticles (LCN) are nanostructured drug delivery systems made of lipid-based amphiphilic materials that self-assemble into crystalline phases in aqueous environments. LCN have become a promising way to treat NSCLC owing to their specific properties that make them useful for targeted delivery and controlled drug release.Areas covered: The review provides a brief overview of the use of LCN in the treatment of NSCLC. It explores their composition, fabrication methods, and characterization processes. The article further addresses several nanoparticle-based approaches for the treatment of NSCLC. Ultimately, it underscores the promise of LCNs as a promising drug delivery system for NSCLC and discusses the obstacles and outlook in this field.Expert opinion: LCN represents a promising frontier in the treatment of NSCLC, offering several specific advantages over conventional therapies. Utilizing their intrinsic self-assembly characteristics, LCN provides meticulous control over drug encapsulation, release kinetics, and cellular absorption, which are crucial for improving therapy success. LCN also has the capability for co-delivery of various drugs, facilitating synergistic therapeutic benefits and addressing multidrug resistance, a prevalent issue in NSCLC treatment.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1-13"},"PeriodicalIF":0.0,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143532265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bringing intranasal drug delivery for malignancies in the brain to market.

Expert opinion on drug delivery Pub Date : 2025-03-01 Epub Date: 2025-02-12 DOI: 10.1080/17425247.2025.2464714

Thomas C Chen, Clovis O da Fonseca, Axel H Schönthal

引用次数: 0

Potential of nanocarrier-mediated delivery of vancomycin for MRSA infections.

Expert opinion on drug delivery Pub Date : 2025-03-01 Epub Date: 2025-02-19 DOI: 10.1080/17425247.2025.2459756

Vincent O Nyandoro, Eman A Ismail, Abdelrahman Tageldin, Mohammed A Gafar, Xylia Q Peters, Relebohile Mautsoe, Calvin A Omolo, Thirumala Govender

{"title":"Potential of nanocarrier-mediated delivery of vancomycin for MRSA infections.","authors":"Vincent O Nyandoro, Eman A Ismail, Abdelrahman Tageldin, Mohammed A Gafar, Xylia Q Peters, Relebohile Mautsoe, Calvin A Omolo, Thirumala Govender","doi":"10.1080/17425247.2025.2459756","DOIUrl":"10.1080/17425247.2025.2459756","url":null,"abstract":"Introduction: Methicillin-resistant Staphylococcus aureus (MRSA) threatens global health due to its resistance to vancomycin, which is the standard treatment despite limitations, including nephrotoxicity and low intracellular permeability. This necessitates the development of innovative strategies such as nanocarrier-mediated delivery to overcome such limitations. Nanocarriers serve as delivery systems for vancomycin and exhibit inherent antibacterial properties, potentially providing synergism and overcoming MRSA's resistance. Nanocarriers provide sustained release and targeted delivery of vancomycin to the infection site, achieving higher therapeutic concentrations and superior antibacterial activity with reduced doses, which minimizes systemic toxicity. Moreover, leveraging simulations techniques provides more insights on vancomycin-nanocarrier interactions, facilitating the optimization of nanosystems.Areas covered: The article discusses the potential of nanocarriers in delivering vancomycin to infection site, reducing systemic toxicity, and potentiating anti-MRSA activity. Additionally, it reviews modeling and simulation studies to provide a deeper understanding of vancomycin-nanocarrier interactions. The literature search included experimental articles from 2017 to 2024, searched in Web of Science, Google scholar, PubMed, and Scopus.Expert opinion: Nanocarrier-mediated delivery of vancomycin offers promising approaches to combat MRSA infections by enhancing therapeutic efficacy and reducing systemic toxicity. However, further research is required to optimize these nanoformulations and advance them to clinical trials and practical applications.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"347-365"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143416615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0